Bleeding Disorder Testing Market Trends

Bleeding Disorder Testing Market Trends

The increasing prevalence of bleeding disorders is projected to drive the demand for precise & timely diagnostics, thereby propelling the industry growth. The rising cases of bleeding disorders such as hemophilia A, hemophilia B, platelet function disorders, hemorrhagic telangiectasia, etc. is set to drive the market growth significantly. For instance, as per the National Centers for Biotechnology Information (NCBI), in 2022, hemophilia A affects around 1 in 5000 males making it the most common congenital coagulopathy; while hemophilia B is an X-linked genetic coagulopathy affects approximately 1 in 30,000 male births in the U.S. This significant prevalence is expected to have a substantial impact on the market, as the number of dependent patients requiring accurate diagnostics increases.
 

Furthermore, patients that undergo diagnosis & are detected with bleeding disorders in the early stage are likely to develop fewer co-morbid conditions and have a lower risk of severe bleeding. Thus, the ever-increasing patient population has significantly increased demand for precise diagnostics, thereby driving the adoption of bleeding disorder testing.